Tiaa Fsb cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 23.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 140,235 shares of the company’s stock after selling 42,669 shares during the period. Tiaa Fsb’s holdings in Eli Lilly and were worth $11,996,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Acrospire Investment Management LLC boosted its position in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and in the 2nd quarter valued at about $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and in the 2nd quarter valued at about $129,000. Point72 Asia Hong Kong Ltd boosted its position in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new stake in Eli Lilly and in the 2nd quarter valued at about $148,000. 76.43% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company (NYSE:LLY) traded up $0.48 during trading hours on Wednesday, hitting $86.06. 3,876,700 shares of the stock traded hands, compared to its average volume of 3,672,667. Eli Lilly and Company has a twelve month low of $66.39 and a twelve month high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The company has a market cap of $94,231.72, a price-to-earnings ratio of 20.92, a P/E/G ratio of 1.88 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the previous year, the business posted $0.88 EPS. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. sell-side analysts expect that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.42%. Eli Lilly and’s dividend payout ratio is currently 98.58%.

Several equities research analysts have issued reports on LLY shares. BMO Capital Markets reissued a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a research report on Thursday, September 28th. Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies reissued a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Jefferies Group reissued a “buy” rating and issued a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $90.25.

In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 628,588 shares of company stock valued at $53,399,536. Company insiders own 0.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Eli Lilly and Company (LLY) Position Lowered by Tiaa Fsb” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/06/eli-lilly-and-company-lly-position-lowered-by-tiaa-fsb.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.